Wall Street is positive on Mirati Therapeutics Inc (MRTX). On average, analysts give MRTX a Buy rating. The average price target is $191, which means analysts expect the stock to rise by 12.87% over the next twelve months. That average ranking earns MRTX an Analyst Rating of 29, which is better than 29% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating MRTX a Buy today. Find out what this means to you and get the rest of the rankings on MRTX!